Rubicon Research Ltd. Stock Analysis RUBICON.NS

Rubicon Research Ltd. engages in the manufacturing and export of formulations spanning a diverse range of dosage forms and therapeutic areas. The company is headquartered in Thane, Maharashtra and currently employs 1,108 full-time employees. The company went IPO on 2025-10-16. Its portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, and topical. Its technologies include RubiReten and RubiSRL. Its services include intellectual property evaluation and product design, formulation research development, analytical research development, technology transfer, dossier compilation and regulatory support, and clinical trials supplies. Its products are spread across many therapeutic areas, such as Analgesics/Pain Management, CVS, CNS, Hypokalemia, Skeletal Muscle Relaxants, NRT, Gastrointestinal, Metabolic, Immunosuppressant, and others. Others include Antipyretic, Hormonal Products, Diuretic, Antimuscarinics, Oral Rehydration Therapy, Over the Counter products, and Respiratory.